Resveratrol, a well-known polyphenol found in grape skins, berries, and other plants, is best known for its cardiovascular health benefits. A quick dive into PubMed yields numerous human studies on resveratrol in the past year alone. These recent studies show benefits for patients with osteoarthritis, cardiometabolic disease, Alzheimer’s disease, COVID-19, polycystic ovarian syndrome (PCOS), and periodontal disease.
Resveratrol was shown to reduce systemic inflammation in multiple studies. This natural compound blocks the NF-κB and NLRP3 signaling pathways and activates SIRT1, inhibiting the production of pro-inflammatory cytokines such as TNF-α, IL-1β and IL-6. Its antioxidant and anti-inflammatory actions make resveratrol a good consideration for patients’ baseline health regimens.
Resveratrol in COVID-19: Clinical Trial Findings
COVID-19 is known to activate inflammation, which involves a cascade of consequences to multiple organ systems. A randomized, double-blinded study1 on 44 patients with COVID-19 showed that 750 mg of resveratrol in divided daily doses for 10 days reduced inflammatory markers compared to placebo. All patients had been admitted to the hospital and had COVID for less than 8 days since the illness started.
There was a statistically significant reduction in C-reactive protein (CRP) (P=0.041), fasting blood glucose (FBG) (P=0.002), alkaline phosphatase (ALP) (P=0.034), IL-1β (P=0.011), TNF-α (P=0.001), white blood cell (P=0.043), platelet count (P=0.042), neutrophils (P=0.015), and an increase in lymphocytes (P=0.010) in the resveratrol group compared to placebo.
These results suggest that resveratrol is involved in the regression of inflammation by affecting the immune system. Inflammation plays a role in insulin resistance, and this study showed that lower inflammatory cytokines, particularly TNF-α, may explain the decrease in FBG. Coagulopathy leading to thrombus formation can be problematic with COVID-19, and this study showed that resveratrol acts as a potential cardioprotective agent by reducing platelets. Resveratrol’s cardiometabolic benefits have been demonstrated in multiple other studies.
Resveratrol for Cardiometabolic and Brain Health
A recent meta-analysis 2 supports the use of resveratrol for cardiometabolic health. The analysis included 40 randomized controlled trials involving 2,551 participants. Resveratrol significantly reduced the homeostatic model assessment of insulin resistance (HOMA-IR), total cholesterol, triglycerides, LDL cholesterol, systolic and diastolic blood pressure, hs-CRP, TNF-α, and IL-6. These results largely support previous meta-analyses, with some variation likely due to dosing, study length, and formulation differences across studies. The decrease in inflammatory cytokines reduces oxidative stress in vascular and metabolic tissues.
You may also like: The Aging Female Heart: Beyond the Male Model of Heart Disease
Resveratrol may also regulate chronic neuroinflammation. The Alzheimer’s Disease Cooperative Study (ADCS)3, a double-blind, placebo-controlled trial, randomized 179 participants to placebo or resveratrol over 52 weeks. Multiple parameters were assessed, and results were published over several years. Participants received 500 mg of resveratrol once daily, with a dose increase of 500 mg increments every 13 weeks, ending with 1000 mg twice daily.
Resveratrol stabilized cerebrospinal fluid amyloid-β levels, regulated microglial activity, and reduced markers of neuroinflammation, including matrix metalloprotease (MMP)-9. Resveratrol’s capacity to inhibit the NLRP3 inflammasome, promote autophagy, and maintain mitochondrial integrity makes it a promising neuroprotective therapeutic candidate.
Conclusions
Numerous clinical studies have demonstrated that resveratrol is an antioxidant, anti-inflammatory, cardioprotective, and neuroprotective agent. Its wide-ranging applications position it as a compelling compound in the prevention and treatment of multiple chronic diseases. Further research is needed to fully establish its clinical efficacy.
→ Click the hyperlinks above to download the FULL TEXT for each study.
References
- Bastin A, Netticadan T, Abbasi F, Rahimi N, Mahmoodi M, Alizadeh M, Movahed A, Momeni-Moghaddam MA. Effects of resveratrol on inflammatory cytokines in COVID-19 patients: a randomized, double-blinded, placebo-controlled clinical trial. Mol Cell Biochem. 2025 Aug;480(8):4865-4872. doi: 10.1007/s11010-025-05290-3. Epub 2025 Apr 30. PMID: 40301181.
- Shen CY, Li CP, Yu JT, Ho YJ, Tsai RY. Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases. In Vivo. 2026 Mar-Apr;40(2):748-783. doi: 10.21873/invivo.14235. PMID: 41760304; PMCID: PMC12949888.
- Liu X, Baxley S, Hebron M, Turner RS, Moussa C. Resveratrol Attenuates CSF Markers of Neurodegeneration and Neuroinflammation in Individuals with Alzheimer’s Disease. Int J Mol Sci. 2025 May 23;26(11):5044. doi: 10.3390/ijms26115044. PMID: 40507855; PMCID: PMC12155158.
